| Detailed information |
|---|
| CancerLivER ID | 2471 |
| Biomarker | Protein disulfide isomerase ER-60, PRBP, Tropomyosin 3, ATP synthase, Dihydropipoamide dehydrogenase, FABP, Cathepsin B1, |
| Biomarker Name/Symbol (given in Publication) | 7-proteins signature ( Protein disulfide isomerase ER-60 (Erp60), Plasma retinal-binding protein precursor (PRBP), Tropomyosin 3, ATP synthase, Dihydropipoamide dehydrogenase, Fatty acie-binding protein (FABP), Cathepsin B1 ) |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | NBNC-associated HCC marker; but not validated on independent dataset |
| Experimental Condition | both (HBV and HCV) negative HCC tumor v/s non-tumorous |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed (FABP, Cathepsin B1 are Downregulated and rest 5 are Upregulated) in HCC tumor v/s non-tumorous |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 14654528 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | Paired tumorous and surrounding nontumorous tissues obtained from 21 HCC patients. They were divided into three HCC types by viral markers: 7 hepatitis B surface antigen-positive (B-type HCC), 7 anti-HCV-positive (C-type HCC), and 7 hepatitis B surface antigen-negative and anti-HCV-negative. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | NBNC-associated HCC |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |